Leap Therapeutics’ (LPTX) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Leap Therapeutics (NASDAQ:LPTX) in a report issued on Thursday,Benzinga reports.

Other analysts have also recently issued research reports about the company. Robert W. Baird cut Leap Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $9.00 to $1.25 in a research report on Wednesday, January 29th. Baird R W lowered Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th.

Leap Therapeutics Stock Down 19.6 %

Shares of LPTX opened at $0.36 on Thursday. Leap Therapeutics has a 52-week low of $0.36 and a 52-week high of $4.79. The stock has a 50 day moving average price of $0.73 and a 200 day moving average price of $2.19. The company has a market capitalization of $13.98 million, a price-to-earnings ratio of -0.19 and a beta of 0.35.

Leap Therapeutics (NASDAQ:LPTX) last posted its earnings results on Wednesday, March 26th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. On average, equities analysts anticipate that Leap Therapeutics will post -1.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Leap Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Prosperity Wealth Management Inc. acquired a new position in Leap Therapeutics in the 4th quarter valued at about $63,000. HighTower Advisors LLC purchased a new position in shares of Leap Therapeutics in the 3rd quarter valued at approximately $65,000. Jane Street Group LLC purchased a new position in shares of Leap Therapeutics in the 4th quarter valued at approximately $107,000. Dauntless Investment Group LLC acquired a new position in shares of Leap Therapeutics in the fourth quarter valued at approximately $144,000. Finally, NewEdge Advisors LLC raised its stake in shares of Leap Therapeutics by 1,668,066.7% during the fourth quarter. NewEdge Advisors LLC now owns 50,045 shares of the company’s stock worth $144,000 after purchasing an additional 50,042 shares during the last quarter. 30.46% of the stock is owned by hedge funds and other institutional investors.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.